当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Kirty T
Thoracic transplantation has revolutionized the treatment of end-stage heart and lung diseases, offering a life-saving option for patients facing organ failure. The abstract highlights the significant advancements in surgical techniques, organ preservation, and immunosuppressive therapies that have contributed to the success of thoracic transplantation procedures. These advancements have resulted in improved patient outcomes, extended survival rates, and enhanced quality of life for recipients. The abstract also addresses the challenges and limitations of thoracic transplantation. These include the shortage of donor organs, the complex process of organ allocation, the risk of rejection, and the potential for post-transplant complications. The abstract acknowledges the importance of ongoing research to address these challenges, optimize immunosuppressive regimens, and develop alternative approaches such as xenotransplantation and regenerative medicine. Ethical considerations surrounding thoracic transplantation, including organ allocation and the use of extended criteria donors, are discussed. The abstract emphasizes the need for equitable and transparent allocation systems that prioritize patients based on medical urgency and suitability. Furthermore, the abstract explores the impact of thoracic transplantation on recipients and their families, highlighting the transformative effect of receiving a new heart or lungs. Improved functional capacity, enhanced respiratory function, and restored cardiac function contribute to an improved quality of life, allowing recipients to engage in activities previously restricted by their condition.